Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab: pharmacovigilance update

Research Alert

Newswise — Background: Limited evidence-based data exist on potential risks of COVID-19 infection in persons with multiple sclerosis (pwMS) receiving immunotherapy. More than 160,000 pwMS have been treated with ocrelizumab (OCR), in clinical trial and real-world settings; data continue to show a consistent and favorable benefit/risk profile.

Objectives: To present a summary of postmarketing pharmacovigilance data (as of May 31, 2020) from pwMS treated with OCR, who have either confirmed or suspected COVID-19.

Methods: Pharmacovigilance-reported adverse event (AE) COVID-19 cases, identified in a search of the Roche Global Safety Database using MedDRA preferred terms and string searches, were defined as valid when at least an identifiable reporter, a single identifiable patient, a medicinal product and a suspected AE were provided. Cases were designated as serious if described by the reporter as serious according to their judgment or if adjudicated as serious by the company when regulatory definitions were met. Patient characteristics and details of OCR treatment were usually provided. All cases were conservatively considered as having confirmed COVID-19. Outcome was classified as recovered, recovering, not recovered, fatal, or not reported.

Results: Of 201 cases, 61% (n=122/201) were reported as non-serious, and 39% (n=79/201) were reported as serious, mostly due to hospitalization (n=51/79). Where known, reasons for hospitalization included, among others, treatment of pneumonia and treatment in ICU. Serious cases were reported as recovered/recovering in 32% (n=25/79) of patients, whilst the outcome was not reported in 33% (n=26/79) of serious cases. A fatal outcome was reported in 5.5% (n=11/201) of patients; risk factors included hypertension, diabetes mellitus, respiratory disease, and malignancy. Updated assessment of the pharmacovigilance cases will be presented.

Conclusions: Taking into account the known limitations of postmarketing safety data, this analysis appears to be in line with published larger case series of non-MS and MS COVID-19 patients. Risk factors in fatal cases were similar to known risk factors reported in the general population.

Presenter: Richard Hughes, F. Hoffmann-La Roche Ltd, , Grenzacherstrasse 124, N/A, Basel, CH




Filters close

Showing results

110 of 3733
Released: 21-Oct-2020 3:40 PM EDT
Pastoral care shown to support older people at risk from COVID-19
Staffordshire University

Volunteers from the Catholic Church in Brazil helped to mitigate the impact of COVID-19 among the elderly, a new study shows.

Newswise: UH Implements Virtual Waiting Room for Patients During COVID-19 Pandemic
Released: 21-Oct-2020 3:30 PM EDT
UH Implements Virtual Waiting Room for Patients During COVID-19 Pandemic
University Hospitals Cleveland Medical Center

UH has implemented PatientTrak, a virtual waiting room that enables the patient to communicate effectively with staff so they can arrive at their appointment on time while avoiding an in-person waiting room.

Released: 21-Oct-2020 3:15 PM EDT
Mass screening method could slash COVID-19 testing costs, trial finds
University of Edinburgh

Using a new mathematical approach to screen large groups for Covid-19 could be around 20 times cheaper than individual testing, a study suggests.

Newswise: 246543_web.jpg
Released: 21-Oct-2020 2:45 PM EDT
Observed COVID-19 variability may have underlying molecular sources
University of California, Riverside

People have different susceptibilities to SARS-CoV-2, the virus behind the COVID-19 pandemic, and develop varying degrees of fever, fatigue, and breathing problems -- common symptoms of the illness. What might explain this variation?

Released: 21-Oct-2020 2:10 PM EDT
Hospitals Leaned Toward Strict COVID-19 NICU Policies Despite Low Prevalence of Infection, New Study Finds
George Washington University

Two studies examining the impact of COVID-19 on neonatal intensive care units (NICUs) found the prevalence of COVID-19 in NICU infants is low, yet many hospitals at the start of the pandemic put in place strict parental visitation policies and scaled back NICU services such as lactation support and therapy.

Newswise: Tracking the SARS-CoV-2 Virus with Genome Sequencing
Released: 21-Oct-2020 2:05 PM EDT
Tracking the SARS-CoV-2 Virus with Genome Sequencing
University of North Carolina School of Medicine

Dirk Dittmer, PhD, professor of microbiology and immunology at the UNC School of Medicine, is tracking the virus that causes COVID-19 by sequencing the genome of virus samples collected from diagnostic testing. Using next generation sequencing on SARS-CoV-2 will help accurately diagnose the novel coronavirus, identify mutations and track its history.

Released: 21-Oct-2020 12:55 PM EDT
Study assessing how early childhood educators spend time away from students
University of Nebraska-Lincoln

Much attention is paid to the work early childhood teachers do in the classroom, but their tasks away from their students can be just as essential to children’s learning and development.

Released: 21-Oct-2020 12:50 PM EDT
Rutgers Pediatricians Sound Alarm on Decreased Flu Vaccinations, Immunizations for Children
Rutgers University-New Brunswick

Two Rutgers New Jersey Medical School pediatricians discuss the importance of keeping children and adults up to date with immunizations during the coronavirus crisis.

Released: 21-Oct-2020 11:35 AM EDT
Trump's claim that House Speaker Nancy Pelosi is to blame for the stalled COVID-19 stimulus legislation is not accurate
Newswise

President Donald Trump has repeatedly blamed the U.S. House Speaker Nancy Pelosi for "not caring about Americans" since she would not agree to his terms for COVID-19 relief aid. We rate these claims as mostly false because they are misleading. According to the New York Times, Senator Mitch McConnell, Republican of Kentucky and the majority leader, told Republican senators privately on Tuesday that he has advised the White House not to strike a deal with Speaker Nancy Pelosi on a new stimulus bill before Election Day.


Showing results

110 of 3733

close
1.12432